Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ryan
A Menter

Showing results (41-50 of 1,260) with videos related to

Pageof 126
Sort By:
Seminars in Dermatology|December 1, 1992
Can maintenance cyclosporine be used in psoriasis without decreasing renal function?A K Silverman, M Emmett, A Menter
Skin Therapy Letter|March 22, 2008
Psoriasis as the marker of underlying systemic diseaseA S Kourosh, A Miner, A Menter
Dermatologic Clinics|October 1, 1995
Tars and anthralinsA Silverman, A Menter, J L Hairston
Clinical and Experimental Dermatology|January 28, 2015
Nodular fasciitis of the lip mucosa: a rare but clinically important entityA A Lloyd, D Witheiler, A Menter
Journal of the American Academy of Dermatology|May 1, 1992
Erythema gyratum repens: a paraneoplastic eruptionA S Boyd, K H Neldner, A Menter
Cutis|October 1, 1989
Recurrent renal cell carcinoma presenting as skin nodules: two case reports and review of the literatureA Menter, A S Boyd, D M McCaffree
Pediatric Dermatology|July 1, 1984
Resistant childhood psoriasis: an analysis of patients seen in a day-care centerM A Menter, D A Whiting, J McWilliams
Clinical and Experimental Dermatology|September 8, 2015
Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumabB Mansouri, D Kivelevitch, M Campa, et al.
Journal of the American Academy of Dermatology|April 1, 1989
Guttate psoriasis and vitiligo: anatomic cohabitationA Menter, A S Boyd, A K Silverman
Journal of the European Academy of Dermatology and Venereology : JEADV|January 9, 2013
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasisC Mamolo, J Harness, H Tan, et al.
Pageof 126

Showing results (41-50 of 1,260) with videos related to

Sort By:
Pageof 126
Seminars in Dermatology|December 1, 1992
Can maintenance cyclosporine be used in psoriasis without decreasing renal function?A K Silverman, M Emmett, A Menter
Skin Therapy Letter|March 22, 2008
Psoriasis as the marker of underlying systemic diseaseA S Kourosh, A Miner, A Menter
Dermatologic Clinics|October 1, 1995
Tars and anthralinsA Silverman, A Menter, J L Hairston
Clinical and Experimental Dermatology|January 28, 2015
Nodular fasciitis of the lip mucosa: a rare but clinically important entityA A Lloyd, D Witheiler, A Menter
Journal of the American Academy of Dermatology|May 1, 1992
Erythema gyratum repens: a paraneoplastic eruptionA S Boyd, K H Neldner, A Menter
Cutis|October 1, 1989
Recurrent renal cell carcinoma presenting as skin nodules: two case reports and review of the literatureA Menter, A S Boyd, D M McCaffree
Pediatric Dermatology|July 1, 1984
Resistant childhood psoriasis: an analysis of patients seen in a day-care centerM A Menter, D A Whiting, J McWilliams
Clinical and Experimental Dermatology|September 8, 2015
Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumabB Mansouri, D Kivelevitch, M Campa, et al.
Journal of the American Academy of Dermatology|April 1, 1989
Guttate psoriasis and vitiligo: anatomic cohabitationA Menter, A S Boyd, A K Silverman
Journal of the European Academy of Dermatology and Venereology : JEADV|January 9, 2013
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasisC Mamolo, J Harness, H Tan, et al.
Pageof 126